DTL has grown top and bottom lines the past 3 years and also improved revenue quality with virtually no increase to operating costs.
Their DCF valuation is about 2x the share price. I took a small position on Friday and will probably add to it over the coming months. Expecting a big kick up when the full year numbers are released.
- Forums
- ASX - By Stock
- DTL
- Well-priced, I am in
Well-priced, I am in
Featured News
Add DTL (ASX) to my watchlist
(20min delay)
|
|||||
Last
$7.59 |
Change
-0.130(1.68%) |
Mkt cap ! $1.184B |
Open | High | Low | Value | Volume |
$7.71 | $7.73 | $7.57 | $1.235M | 161.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
26 | 13526 | $7.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$7.59 | 3617 | 34 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 11811 | 7.580 |
12 | 4967 | 7.570 |
9 | 3817 | 7.560 |
9 | 28959 | 7.550 |
5 | 11504 | 7.540 |
Price($) | Vol. | No. |
---|---|---|
7.600 | 3397 | 15 |
7.610 | 3676 | 12 |
7.620 | 3992 | 10 |
7.630 | 6096 | 9 |
7.640 | 1744 | 5 |
Last trade - 13.39pm 13/11/2024 (20 minute delay) ? |
Featured News
DTL (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online